In-111 Pentetreotide SRS: Physics and QC

In-111 pentetreotide (OctreoScan) somatostatin receptor scintigraphy localizes neuroendocrine tumors by imaging a gamma emitter that decays by electron capture with principal photopeaks near 171 and 245 keV, using a medium-energy collimator and dual energy windows. A diagnostic-quality study depends on correct administered activity, standardized 4- and 24-hour imaging, disciplined camera quality control, and dosimetry and licensing that follow established nuclear-medicine physics standards.¹²¹¹¹²

The physics of In-111 is what drives every practical decision in this exam: the electron-capture decay scheme sets the photon energies, the photon energies set the collimator and energy-window choices, and the biodistribution and physical half-life of about 67.3 hours set the imaging schedule and the patient dose.⁸¹⁰¹¹ This guide walks through that chain from decay data to protocol to QC to regulation.

Introduction

Somatostatin receptor scintigraphy (SRS) with In-111 pentetreotide was, through August 2023, a well-established functional imaging method for somatostatin-receptor-positive neuroendocrine tumors (NETs). The tracer is a diethylenetriaminepentaacetic acid (DTPA)-conjugated octreotide analog labeled with indium-111. It binds preferentially to somatostatin receptor subtype 2, which is highly expressed on many gastroenteropancreatic and bronchial NETs, allowing whole-body detection of primary and metastatic disease.³⁴⁶

From a medical physics standpoint, In-111 is a comparatively demanding single-photon radionuclide. Its two principal gamma emissions are more energetic than the 140 keV photon of Tc-99m, so collimator selection, energy windowing, scatter behavior, and camera QC all have to be handled deliberately.¹² The 2.8-day physical half-life also permits — and clinically benefits from — delayed imaging at 24 and sometimes 48 hours, which shapes both the acquisition schedule and the radiation dosimetry.¹⁸

This article explains the In-111 decay physics, the standard SRS acquisition protocol, a worked decay-math example, patient dosimetry, quality control, clinical impact, optimization tips, and the NRC materials-licensing context that governs use in a clinical nuclear medicine program.^110111314

Topic Explanation

What is In-111 pentetreotide somatostatin receptor scintigraphy?

In-111 pentetreotide SRS is a nuclear medicine study in which a radiolabeled somatostatin analog is injected intravenously, allowed to bind to somatostatin-receptor-positive tissue, and imaged with a gamma camera to localize neuroendocrine tumors. OctreoScan is supplied as a kit for the preparation of indium In-111 pentetreotide, radiolabeled on site before administration.¹²

Key terms used throughout this guide:

• Pentetreotide — the DTPA-octreotide peptide conjugate that both chelates In-111 and binds somatostatin receptors.
• Somatostatin receptor subtype 2 (sstr2) — the receptor subtype most responsible for tumor uptake of the tracer.⁶
• Photopeak — an energy window centered on a characteristic gamma emission used to form the image.
• Medium-energy collimator — a parallel-hole collimator with septa designed for photons in roughly the 150 to 300 keV range.

Why is the decay physics of In-111 central?

In-111 decays 100% by electron capture to stable cadmium-111, with a physical half-life of 2.805 days, or about 67.3 hours.¹¹ Electron capture produces an excited Cd-111 nucleus that promptly emits two principal gamma photons at 171.3 keV (about 90.7% per decay) and 245.4 keV (about 94.1% per decay).¹¹ There is no positron and no high-yield high-energy photon that would require heavy shielding of the imaging suite, but the two photopeaks are energetic enough to penetrate low-energy collimator septa.

Because both gamma yields are high and close to one per decay, both photopeaks are used to form the image. This is why In-111 SRS is acquired with dual, symmetric energy windows and a medium-energy collimator rather than the single low-energy window used for Tc-99m.¹² For the general framework behind matching a collimator to a photon energy, see our overview of gamma camera collimator selection.

What determines tumor uptake?

Uptake reflects receptor biology, not perfusion alone. Preclinical work using somatostatin-receptor knockout models demonstrated that sstr2 is the dominant determinant of In-111 pentetreotide accumulation in receptor-positive organs, which explains both tumor targeting and the physiologic uptake seen in the spleen, kidneys, liver, pituitary, and thyroid.⁶ The large clinical series established the sensitivity of the method across gastroenteropancreatic and other NETs and its impact on patient management.³⁴⁵⁷

Key Technical Principles

In-111 decay data and the physical half-life

The imaging schedule and dosimetry both rest on the physical half-life. With a half-life $T_{1/2}=67.3$ h, the decay constant is:¹¹

The activity remaining at time $t$ after calibration follows the standard decay law:

For an administered activity of $A_0=222$ MBq imaged at 24 hours, the remaining activity is:

At the optional 48-hour time point the decay factor is $e^{-0.0103\times 48}\approx 0.610$, leaving about 135 MBq. This slow physical decay is exactly why delayed imaging remains count-rich enough to be diagnostic, and why background clearance — rather than radioactive decay — is the main reason later images improve target-to-background contrast.¹⁸

Acquisition parameters: planar versus SPECT

The table below summarizes representative In-111 pentetreotide SRS acquisition settings consistent with the SNMMI/SNM procedure guidelines and the product labeling. Values are typical ranges; site protocols should be set with the interpreting physician and qualified medical physicist.¹²¹²

Acquiring both photopeaks improves counting statistics, which matters because In-111 administered activity is far lower than a typical Tc-99m study and the count rate is correspondingly modest. The medium-energy collimator is what makes the dual-window strategy work without unacceptable septal penetration.¹²

Why medium-energy collimation and dual windows

A collimator is chosen so that septal penetration stays small relative to the geometrically collimated signal. For the 245 keV photon in particular, a low-energy collimator would allow substantial penetration through the septa, producing a diffuse background, star or streak artifacts, and degraded resolution and contrast. The thicker septa of a medium-energy collimator suppress that penetration at the cost of some sensitivity and resolution, which is the correct trade for In-111.¹²

Symmetric energy windows of about 15 to 20 percent on each photopeak balance scatter rejection against count sensitivity. Both windows are summed to form the image. Because down-scatter from the 245 keV photon can contaminate the 171 keV window, correct peaking on both photopeaks and correct collimation are essential to preserve quantitative and visual image quality.¹² SPECT further benefits from attenuation and scatter handling; our discussion of SPECT/CT attenuation correction covers the general principles that also apply to In-111 tomography.

Counting statistics and delayed imaging

Because the administered activity and count rate are low, image quality is statistics-limited. The fractional noise in a region containing $N$ counts scales as:

Doubling the counts collected — for example by using both photopeaks or a longer acquisition — reduces fractional noise by a factor of about $\sqrt{2}$. This is why adequate scan time, both energy windows, and appropriate matrix selection are not optional details in In-111 SRS; they directly govern lesion detectability. The statistical basis for this is developed further in our guide to nuclear medicine counting statistics.¹

Clinical Impact

Somatostatin receptor scintigraphy changed the diagnostic pathway for neuroendocrine tumors by adding whole-body, receptor-specific functional imaging to anatomic modalities. The Rotterdam experience in more than 1,000 patients established that a wide range of NETs could be localized in vivo with radiolabeled octreotide, including primaries and metastases that were occult on conventional imaging.³

Subsequent series reinforced the clinical value. In gastroenteropancreatic NETs, In-111 pentetreotide was shown to be safe and sensitive and to change patient management by detecting additional disease sites.⁵ Multi-institutional experience reported agreement with conventional imaging for the majority of tumor locations while identifying additional lesions not seen by other methods, including small duodenal gastrinomas — although insulinomas, which less reliably express sstr2, are imaged poorly.⁷ The consolidated single-institution experience similarly ranked SRS as a prime imaging procedure for suspected NETs.⁴

The physics enables the clinical value. Receptor-specific uptake, whole-body coverage, and delayed imaging that exploits the 2.8-day half-life together produce high tumor-to-background contrast for sstr2-positive disease.¹⁶ Understanding both the strengths and the limits — such as poor insulinoma detection and physiologic bowel, splenic, and renal uptake that can mimic or obscure lesions — is essential to accurate interpretation.⁴⁷

Practical Optimization Tips

Standardize acquisition and reduce interfering activity

• Peak on both photopeaks before every study. Confirm the camera is peaked at 171 and 245 keV with the intended window widths; an off-peak setting silently degrades contrast.¹²
• Use the correct medium-energy collimator. Verify the installed collimator matches the protocol; a low-energy collimator left on the detector is a common, avoidable error that ruins In-111 images.¹
• Image at standardized times. Acquire at about 4 and 24 hours, and add 48-hour imaging when bowel activity or an equivocal focus needs clarification.¹⁵
• Manage bowel activity. Because a small fraction of the tracer is excreted hepatobiliary and physiologic bowel uptake occurs, some protocols use a mild laxative preparation to reduce abdominal background before delayed imaging; follow the interpreting physician's protocol.¹
• Consider somatostatin analog timing. Ongoing octreotide therapy can affect receptor availability and biodistribution; coordinate any hold with the referring team per institutional protocol.¹

Add SPECT and use adequate counts

Planar imaging provides whole-body survey, but SPECT or SPECT/CT of a region of interest improves lesion localization and detection, especially in the abdomen where overlapping physiologic uptake complicates planar reading.¹² Because the study is statistics-limited, do not shortchange SPECT time per projection; the noise reduction from adequate counts directly improves small-lesion conspicuity.

Verify the prepared dose

• Confirm radiochemical purity of the freshly prepared kit meets the labeled specification before administration.¹²
• Verify dose-calibrator accuracy and the In-111 setting so administered activity is correct; both under- and over-dosing degrade the study or the dose profile.
• Record administered activity, time, and route, consistent with medical-use recordkeeping expectations.¹³

Regulatory Considerations

In-111 is byproduct material, so its medical use is governed by NRC or Agreement State regulations rather than by X-ray machine rules. Possession and medical use fall under 10 CFR Part 35 (Medical Use of Byproduct Material), with radiation protection standards, occupational and public dose limits, and survey and recordkeeping requirements set by 10 CFR Part 20.¹³¹⁴

Key program elements for an In-111 SRS service include:

• Authorized user and license. In-111 pentetreotide must be administered under an authorized user working within the scope of a radioactive material license and the medical-use requirements of 10 CFR Part 35.¹³
• Radiation protection program. Dose limits, ALARA, area surveys, package receipt surveys, and dose-calibrator and instrument QC follow 10 CFR Part 20 and the license conditions.¹⁴
• Jurisdiction. DRPS serves facilities across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware. Most of these are NRC Agreement States for radioactive material; Washington DC and Delaware are regulated directly by the NRC. X-ray-producing devices such as the CT in a SPECT/CT are separately regulated by the FDA and state radiation-control programs. Always confirm requirements with the authority having jurisdiction.¹³¹⁴

Patient dosimetry supports both protocol design and regulatory documentation. Published dosimetry for In-111 pentetreotide identifies the kidneys as the organ receiving the highest dose, about 0.52 mGy/MBq, with an effective dose of about 0.073 mSv/MBq; the spleen, liver, and bladder wall also receive relatively high doses owing to receptor uptake and renal excretion.⁸ Standardized dose coefficients for In-111 radiopharmaceuticals and the underlying nuclear decay data are compiled in ICRP Publications 128 and 107, respectively.¹⁰¹¹ For programs managing the materials license itself, see our overview of radioactive material license renewal.

Frequently Asked Questions (FAQs)

What is In-111 pentetreotide (OctreoScan) used for?

In-111 pentetreotide is a radiolabeled somatostatin analog used for somatostatin receptor scintigraphy to localize primary and metastatic neuroendocrine tumors that overexpress somatostatin receptors, particularly subtype 2. It also visualizes some other receptor-positive lesions such as certain granulomas and activated lymphocytes.³⁴⁶

Why does In-111 imaging require a medium-energy collimator?

In-111 emits two relatively high-energy gamma photons at about 171 and 245 keV. A medium-energy collimator provides thicker septa that limit septal penetration and down-scatter from those photons, preserving spatial resolution and contrast. A low-energy collimator would allow excessive penetration and degrade image quality.¹²

How much In-111 pentetreotide is administered and when is imaging performed?

Typical administered activity is about 111 MBq (3 mCi) for planar imaging and up to about 222 MBq (6 mCi) when SPECT is planned. Whole-body and SPECT images are commonly obtained at approximately 4 hours and 24 hours after injection, with optional 48-hour imaging to clarify bowel activity or equivocal findings.¹¹²

What energy windows are used for In-111 scintigraphy?

Both photopeaks are acquired simultaneously using symmetric energy windows, commonly 15 to 20 percent, centered on the 171 keV and 245 keV photopeaks. Using both windows increases counting statistics while a medium-energy collimator controls the associated scatter and penetration.¹²¹¹

What is the radiation dose from an In-111 pentetreotide study?

The kidneys receive the highest organ dose, on the order of 0.5 mGy per MBq, and the spleen, liver, and bladder wall also receive relatively high doses because of receptor uptake and renal excretion. The effective dose is roughly 0.073 mSv per MBq, so a 111 to 222 MBq study corresponds to an effective dose of about 8 to 16 mSv.⁸¹⁰

What quality control supports a reliable In-111 study?

Routine gamma camera QC includes daily uniformity, periodic spatial resolution and linearity, energy-peaking on both In-111 photopeaks, and SPECT center-of-rotation and multi-detector registration checks. Radiochemical purity of the prepared kit and dose-calibrator accuracy for In-111 are also verified before administration.¹²¹²

Who regulates In-111 pentetreotide use in a clinic?

As a byproduct material, In-111 use is regulated under 10 CFR Part 35 for medical use and 10 CFR Part 20 for radiation protection, administered by the NRC or an Agreement State. Facilities must work under an authorized user and radioactive material license, with a qualified medical physicist and radiation safety officer supporting QC and safety.¹³¹⁴

Key Takeaways

• In-111 decays 100% by electron capture with a 2.805-day (about 67.3 h) half-life and principal gamma photopeaks at 171.3 keV and 245.4 keV.¹¹
• Both photopeaks are imaged with dual, symmetric 15 to 20 percent energy windows and a medium-energy collimator to control septal penetration and scatter.¹²
• Typical administered activity is about 111 MBq (3 mCi) for planar and up to about 222 MBq (6 mCi) for SPECT, imaged at roughly 4 and 24 hours with optional 48-hour imaging.¹¹²
• Tumor uptake is driven predominantly by somatostatin receptor subtype 2, giving high target-to-background contrast for sstr2-positive NETs but poor insulinoma detection.⁶⁷
• The kidneys receive the highest organ dose (about 0.52 mGy/MBq) and the effective dose is about 0.073 mSv/MBq, so a study is roughly 8 to 16 mSv.⁸¹⁰
• In-111 is byproduct material regulated under 10 CFR Parts 35 and 20 by the NRC or an Agreement State.¹³¹⁴

Conclusion

In-111 pentetreotide somatostatin receptor scintigraphy is a physics-driven exam: the electron-capture decay scheme sets the 171 and 245 keV photopeaks, the photon energies mandate medium-energy collimation and dual energy windows, the 2.8-day half-life enables delayed 24- and 48-hour imaging, and receptor biology governs the biodistribution and dosimetry. A diagnostic-quality, defensible study combines the standardized SNMMI/SNM acquisition protocol, disciplined camera QC, verified administered activity, dosimetry consistent with ICRP data, and materials-license compliance under NRC or Agreement State rules.^12810111314 Somatostatin-receptor PET was, as of August 2023, an emerging alternative for receptor imaging, but the established SRS technique described here remained a widely used and well-characterized study.

How DRPS Can Help

Diagnostic Radiation Physics Services (DRPS) supports nuclear medicine and PET/CT programs across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware with PET/CT and nuclear medicine physics, gamma camera and SPECT/CT acceptance and annual testing, In-111 protocol and QC review, dose-calibrator and instrument QC, dosimetry documentation, and radiation safety officer support prepared by board-certified medical physicists.

A strong In-111 SRS program is not just about acquiring an image. It is about matching collimation, energy windowing, timing, and QC to the physics of the radionuclide so that the study is accurate, reproducible, and compliant with the applicable materials license.

Related Resources

• Gamma camera collimator selection
• SPECT/CT attenuation correction
• Nuclear medicine counting statistics
• Common PET & RPT isotopes
• Radioactive material license renewal
• PET/CT and nuclear medicine physics services
• Radiation safety officer services

References

1. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med. 2001;42(7):1134-1138. pubmed.ncbi.nlm.nih.gov
2. Balon HR, Brown TLY, Goldsmith SJ, et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol. 2011;39(4):317-324. doi:10.2967/jnmt.111.098277. doi.org
3. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716-731. doi:10.1007/BF00181765. doi.org
4. Olsen JO, Pozderac RV, Hinkle G, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25(3):251-261. doi:10.1016/s0001-2998(95)80014-x. doi.org
5. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995;36(4):542-549. pubmed.ncbi.nlm.nih.gov
6. Hofland LJ, Lamberts SWJ, van Hagen PM, et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med. 2003;44(8):1315-1321. pubmed.ncbi.nlm.nih.gov
7. Ellison EC, Schirmer WJ, Olsen JO, et al. Localization of neuroendocrine tumors using somatostatin receptor imaging with indium-111-pentetreotide (OctreoScan). Cancer Control. 1997;4(1):35-39. pubmed.ncbi.nlm.nih.gov
8. Stabin MG, Kooij PP, Bakker WH, et al. Radiation dosimetry for indium-111-pentetreotide. J Nucl Med. 1997;38(12):1919-1922. pubmed.ncbi.nlm.nih.gov
9. Bombardieri E, Ambrosini V, Aktolun C, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37(7):1441-1448. doi:10.1007/s00259-010-1473-6. doi.org
10. International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. ICRP Publication 128. Ann ICRP 44(2S). Thousand Oaks, CA: SAGE; 2015. icrp.org
11. International Commission on Radiological Protection. Nuclear Decay Data for Dosimetric Calculations. ICRP Publication 107. Ann ICRP 38(3). Amsterdam: Elsevier; 2008. icrp.org
12. Mallinckrodt Nuclear Medicine LLC. OctreoScan (kit for the preparation of indium In-111 pentetreotide) Prescribing Information. Maryland Heights, MO: Mallinckrodt. dailymed.nlm.nih.gov
13. U.S. Nuclear Regulatory Commission. 10 CFR Part 35, Medical Use of Byproduct Material. nrc.gov
14. U.S. Nuclear Regulatory Commission. 10 CFR Part 20, Standards for Protection Against Radiation. nrc.gov